MedPath

ABBVIE

ABBVIE logo
🇺🇸United States
Ownership
-
Established
2013-01-01
Employees
-
Market Cap
$346B
Website
http://www.abbvie.com

Study to Assess Change in Quality of Life of Risankizumab Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis

Not yet recruiting
Conditions
Plaque Psoriasis
First Posted Date
2025-06-26
Last Posted Date
2025-06-26
Lead Sponsor
AbbVie
Target Recruit Count
700
Registration Number
NCT07039110

A Study to Assess Safety and Effectiveness of HArmonyCa Lidocaine Injectable Gel for Restoration and/or Creation of Mid-Face Volume in Adult Participants

Phase 3
Recruiting
Conditions
Mid Face Volume Deficit
First Posted Date
2025-06-24
Last Posted Date
2025-06-24
Lead Sponsor
AbbVie
Target Recruit Count
252
Registration Number
NCT07032597
Locations
🇨🇳

Beijing Hospital /ID# 272476, Beijing, Beijing, China

🇨🇳

Peking Union Medical College Hospital (West) - Xidan Campus /ID# 272480, Beijing, Beijing, China

🇨🇳

Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 272631, Wuhan, Hubei, China

and more 6 locations

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Phase 2
Not yet recruiting
Conditions
Gynecologic Cancers
Platinum-Sensitive Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer (PSOC)
Interventions
First Posted Date
2025-06-17
Last Posted Date
2025-06-17
Lead Sponsor
AbbVie
Target Recruit Count
350
Registration Number
NCT07024784

Study to Assess the Adverse Events, Tolerability, and How Oral Doses of ABBV-932 Moves Through the Body in Healthy Adult Chinese Participants

Phase 1
Not yet recruiting
Conditions
Healthy Volunteer
Interventions
Drug: Placebo for ABBV-932
First Posted Date
2025-06-17
Last Posted Date
2025-06-17
Lead Sponsor
AbbVie
Target Recruit Count
30
Registration Number
NCT07024797

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants in Japan With Alopecia Areata

Phase 3
Not yet recruiting
Conditions
Alopecia Areata
Interventions
Drug: Upadacitinib Placebo
First Posted Date
2025-06-16
Last Posted Date
2025-06-16
Lead Sponsor
AbbVie
Target Recruit Count
123
Registration Number
NCT07023302

Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Phase 3
Not yet recruiting
Conditions
Neovascular Age-related Macular Degeneration
Interventions
Drug: Surabgene Lomparvovec (ABBV-RGX-314)
Drug: Ranibizumab Control
First Posted Date
2025-06-05
Last Posted Date
2025-06-05
Lead Sponsor
AbbVie
Target Recruit Count
561
Registration Number
NCT07007065

A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants

Phase 1
Recruiting
Conditions
Healthy Volunteers
Interventions
First Posted Date
2025-06-05
Last Posted Date
2025-06-18
Lead Sponsor
AbbVie
Target Recruit Count
252
Registration Number
NCT07007091
Locations
🇺🇸

Ppd - Las Vegas Research Unit /ID# 276565, Las Vegas, Nevada, United States

🇺🇸

Cpmi /Id# 276490, Miami, Florida, United States

🇺🇸

Acpru /Id# 276043, Grayslake, Illinois, United States

and more 1 locations

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

Phase 2
Not yet recruiting
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
Drug: Standard of Care
Drug: Osimertinib (Osi)
First Posted Date
2025-06-05
Last Posted Date
2025-06-05
Lead Sponsor
AbbVie
Target Recruit Count
694
Registration Number
NCT07005102
© Copyright 2025. All Rights Reserved by MedPath